Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million , Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn. --(BUSINESS WIRE)--Jul. 8, 2025-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific